

University of Groningen

## A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency virus drug treatment

Daskapan, Alper

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2018

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Daskapan, A. (2018). *A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency virus drug treatment*. Rijksuniversiteit Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

A quest to optimize the clinical  
pharmacology of tuberculosis  
and human immunodeficiency  
virus drug treatment

Alper Daskapan

Daskapan, A.

A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency virus drug treatment

Thesis, University of Groningen, the Netherlands

Publication of this thesis was financially supported by University of Groningen, University Medical Center Groningen, Graduate School of Medical Sciences, KNCV Tuberculosis Foundation, Royal Dutch Pharmacists Association (KNMP) and Stichting Beatrixoord Noord-Nederland.



**Stichting  
Beatrixoord  
Noord-  
Nederland**

|            |  |
|------------|--|
| Cover      | Andries de Vries                       |
| Lay-out    | ProefschriftenPrinten.nl               |
| Printed by | ProefschriftenPrinten.nl               |
| ISBN:      | 978-94-034-1162-0                      |
| ISBN:      | 978-94-034-1161-3 (electronic version) |

© Copyright 2018 A. Daskapan, Groningen, The Netherlands

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, by photocopying, recording or otherwise, without the prior written permission of the author.



**rijksuniversiteit  
 groningen**

# **A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency virus drug treatment**

## **Proefschrift**

ter verkrijging van de graad van doctor aan de  
 Rijksuniversiteit Groningen  
 op gezag van de  
 rector magnificus prof. dr. E. Sterken  
 en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op  
 woensdag 21 november 2018 om 12.45 uur

door

**Alper Daskapan**

geboren op 2 juli 1990  
 te 's-Gravenhage

**Promotores**

Prof. dr. T.S. van der Werf

Dr. J.W.C. Alffenaar

Prof. dr. Y. Stienstra

**Beoordelingscommissie**

Prof. dr. D.M. Burger

Prof. dr. M.A. van Agtmael

Prof. dr. H.W. Frijlink

## TABLE OF CONTENTS

|                   |   |     |
|-------------------|---|-----|
| <b>Chapter 1</b>  | General introduction  | 7   |
| <b>Chapter 2</b>  | A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs   | 17  |
| <b>Chapter 3</b>  | Predictors of prolonged TB treatment in a Dutch outpatient setting  | 47  |
| <b>Chapter 4</b>  | Letters to the editor and case-report   | 63  |
| <b>A</b>          | The never ending struggle against development of drug resistance  | 65  |
| <b>B</b>          | The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection                                     | 69  |
| <b>C</b>          | Raltegravir and rifampicin in patients with HIV and tuberculosis  | 75  |
| <b>Chapter 5</b>  | Development and validation of a bioanalytical method for the simultaneous determination of 14 antiretroviral drugs using liquid chromatography-tandem mass spectrometry | 79  |
| <b>Chapter 6</b>  | Darunavir population pharmacokinetic model based on HIV outpatient data   | 99  |
| <b>Chapter 7</b>  | Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting  | 117 |
| <b>Chapter 8</b>  | Risk factors contributing to a low darunavir plasma concentration   | 129 |
| <b>Chapter 9</b>  | General Discussion and Future Perspectives  | 141 |
| <b>Chapter 10</b> | Summary   | 153 |
| <b>Chapter 11</b> | Samenvatting  | 159 |
|                   | Dankwoord   | 166 |
|                   | Curriculum Vitae  | 172 |
|                   | Publication List  | 174 |

